CA2455510A1 - A hemostatic composition - Google Patents
A hemostatic composition Download PDFInfo
- Publication number
- CA2455510A1 CA2455510A1 CA002455510A CA2455510A CA2455510A1 CA 2455510 A1 CA2455510 A1 CA 2455510A1 CA 002455510 A CA002455510 A CA 002455510A CA 2455510 A CA2455510 A CA 2455510A CA 2455510 A1 CA2455510 A1 CA 2455510A1
- Authority
- CA
- Canada
- Prior art keywords
- composition
- core particles
- group
- particulate material
- coating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract 34
- 230000002439 hemostatic effect Effects 0.000 title claims abstract 6
- 239000007771 core particle Substances 0.000 claims abstract 22
- 239000011236 particulate material Substances 0.000 claims abstract 13
- 239000011248 coating agent Substances 0.000 claims abstract 11
- 238000000576 coating method Methods 0.000 claims abstract 11
- 239000002245 particle Substances 0.000 claims abstract 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract 8
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims abstract 8
- 229910017052 cobalt Inorganic materials 0.000 claims abstract 6
- 239000010941 cobalt Substances 0.000 claims abstract 6
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 claims abstract 6
- 229920000642 polymer Polymers 0.000 claims abstract 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract 4
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims abstract 4
- 229910000831 Steel Inorganic materials 0.000 claims abstract 4
- 229910052799 carbon Inorganic materials 0.000 claims abstract 4
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims abstract 4
- 229910052737 gold Inorganic materials 0.000 claims abstract 4
- 239000010931 gold Substances 0.000 claims abstract 4
- 229910052697 platinum Inorganic materials 0.000 claims abstract 4
- 239000000377 silicon dioxide Substances 0.000 claims abstract 4
- 229910052709 silver Inorganic materials 0.000 claims abstract 4
- 239000004332 silver Substances 0.000 claims abstract 4
- 239000010959 steel Substances 0.000 claims abstract 4
- 239000012530 fluid Substances 0.000 claims 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 4
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims 4
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims 4
- 230000000740 bleeding effect Effects 0.000 claims 4
- 239000003805 procoagulant Substances 0.000 claims 4
- 230000005291 magnetic effect Effects 0.000 claims 3
- 102100023804 Coagulation factor VII Human genes 0.000 claims 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 2
- 229920002307 Dextran Polymers 0.000 claims 2
- 108010023321 Factor VII Proteins 0.000 claims 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 2
- 229930195725 Mannitol Natural products 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 108090000190 Thrombin Proteins 0.000 claims 2
- 239000000956 alloy Substances 0.000 claims 2
- 229910045601 alloy Inorganic materials 0.000 claims 2
- 210000001772 blood platelet Anatomy 0.000 claims 2
- 229910000428 cobalt oxide Inorganic materials 0.000 claims 2
- IVMYJDGYRUAWML-UHFFFAOYSA-N cobalt(ii) oxide Chemical compound [Co]=O IVMYJDGYRUAWML-UHFFFAOYSA-N 0.000 claims 2
- 229910003460 diamond Inorganic materials 0.000 claims 2
- 239000010432 diamond Substances 0.000 claims 2
- 239000002270 dispersing agent Substances 0.000 claims 2
- 229940012413 factor vii Drugs 0.000 claims 2
- 229910052742 iron Inorganic materials 0.000 claims 2
- 230000001788 irregular Effects 0.000 claims 2
- 239000008101 lactose Substances 0.000 claims 2
- 230000003902 lesion Effects 0.000 claims 2
- 239000000594 mannitol Substances 0.000 claims 2
- 235000010355 mannitol Nutrition 0.000 claims 2
- 229910052759 nickel Inorganic materials 0.000 claims 2
- 229910000480 nickel oxide Inorganic materials 0.000 claims 2
- 231100000252 nontoxic Toxicity 0.000 claims 2
- 230000003000 nontoxic effect Effects 0.000 claims 2
- GNRSAWUEBMWBQH-UHFFFAOYSA-N oxonickel Chemical compound [Ni]=O GNRSAWUEBMWBQH-UHFFFAOYSA-N 0.000 claims 2
- 210000002381 plasma Anatomy 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 229920000136 polysorbate Polymers 0.000 claims 2
- 239000000600 sorbitol Substances 0.000 claims 2
- 239000004094 surface-active agent Substances 0.000 claims 2
- 229960004072 thrombin Drugs 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 239000006249 magnetic particle Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000005298 paramagnetic effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/02—Surgical adhesives or cements; Adhesives for colostomy devices containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4833—Thrombin (3.4.21.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/501—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5094—Microcapsules containing magnetic carrier material, e.g. ferrite for drug targeting
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
Abstract
A hemostatic composition includes a carrier medium including a predetermined amount of a particulate material. The particulate material is comprised of core particles with a coating. The core particles have an average particle size of about 5 nm to 10 pm, and the coating is one of gold, silica, silver, platinum, steel, cobalt, carbon, a polymer, or a combination thereof.
Claims (32)
1. A hemostatic composition, comprising:
a) a carrier medium;
b) a predetermined amount of a particulate material in said medium;
c) said particulate material comprising core particles with a coating;
d) said core particles having an average particle size of about 5 nm to 10 µm; and e) said coating comprising a member selected from the group consisting of gold, silica, silver, platinum, steel, cobalt, carbon, a polymer, procoagulant molecules, and a combination thereof.
a) a carrier medium;
b) a predetermined amount of a particulate material in said medium;
c) said particulate material comprising core particles with a coating;
d) said core particles having an average particle size of about 5 nm to 10 µm; and e) said coating comprising a member selected from the group consisting of gold, silica, silver, platinum, steel, cobalt, carbon, a polymer, procoagulant molecules, and a combination thereof.
2. The composition of Claim 1, wherein:
a) said core particles comprise a member selected from the group consisting of iron, iron oxide, cobalt, cobalt oxide, nickel, nickel oxide, and an alloy or a combination thereof.
a) said core particles comprise a member selected from the group consisting of iron, iron oxide, cobalt, cobalt oxide, nickel, nickel oxide, and an alloy or a combination thereof.
3. The composition of Claim 1, wherein:
a) said core particles have an average particle size of about 10 nm to 1 µm.
a) said core particles have an average particle size of about 10 nm to 1 µm.
4. The composition of Claim 1, wherein:
a) said core particles have an average particle size of about 10 nm to 300 nm.
a) said core particles have an average particle size of about 10 nm to 300 nm.
5. The composition of Claim 1, wherein:
a) said core particles comprise a general shape selected from the group consisting of a sphere, a needle, a cube, an oval, irregular, a cylinder, a diamond, and a combination thereof.
a) said core particles comprise a general shape selected from the group consisting of a sphere, a needle, a cube, an oval, irregular, a cylinder, a diamond, and a combination thereof.
6. The composition of Claim 1, wherein:
a) said core particles comprise clusters.
a) said core particles comprise clusters.
7. The composition of Claim 1, wherein:
a) said core particles comprise the general shape of blood platelets.
a) said core particles comprise the general shape of blood platelets.
8. The composition of Claim 1, wherein:
a) said polymer is selected from the group consisting of polyethylene glycol, dextran, Tween, sorbitol, mannitol, and a combination thereof.
a) said polymer is selected from the group consisting of polyethylene glycol, dextran, Tween, sorbitol, mannitol, and a combination thereof.
9. The composition of Claim 1, wherein:
a) said coating has a thickness of about 1 nm to 1 µm.
a) said coating has a thickness of about 1 nm to 1 µm.
10. The composition of Claim 1, wherein:
a) said coating has a thickness of about 5nm to 50nm.
a) said coating has a thickness of about 5nm to 50nm.
11. The composition of Claim 1, wherein:
a) said procoagulant molecules are selected from the group consisting of thrombin and Factor VII a.
a) said procoagulant molecules are selected from the group consisting of thrombin and Factor VII a.
12. The composition of Claim 1, further comprising:
a) a surfactant or dispersant.
a) a surfactant or dispersant.
13. The composition of Claim 1, wherein:
a) the concentration of said particulate material is about 0.1% to 70% (w/w) of the composition.
a) the concentration of said particulate material is about 0.1% to 70% (w/w) of the composition.
14. The composition of Claim 1, wherein:
a) said particulate material is non-toxic to bio-cells or biomolecules.
a) said particulate material is non-toxic to bio-cells or biomolecules.
15. The composition of Claim 1, wherein:
a) said carrier is selected from the group consisting of water, saline solution, sugar solution, Lactose Ringers, and blood plasma.
a) said carrier is selected from the group consisting of water, saline solution, sugar solution, Lactose Ringers, and blood plasma.
16. The composition of Claim 1, wherein:
a) said core particles have a narrow distribution of sizes.
a) said core particles have a narrow distribution of sizes.
17. A magnetic hemostatic fluid for controlling external or internal bleeding in a subject, comprising:
a) a carrier fluid;
b) a predetermined amount of a magnetic particulate material in said fluid;
c) said particulate material comprising core particles with a coating having a thickness of about 1 nm to 10 µm;
d) said core particles having an average particle size of about 5 nm to 10 µm;
a) a carrier fluid;
b) a predetermined amount of a magnetic particulate material in said fluid;
c) said particulate material comprising core particles with a coating having a thickness of about 1 nm to 10 µm;
d) said core particles having an average particle size of about 5 nm to 10 µm;
18 e) said core particles comprising a member selected from the group consisting of iron, iron oxide, cobalt, cobalt oxide, nickel, nickel oxide, and an alloy or a combination thereof;
and f) said coating comprising a member selected from the group consisting of gold, silica, silver, platinum, steel, cobalt, carbon, a polymer, and a combination thereof.
18. The composition of Claim 17, wherein:
a) said core particles have an average particle size of about 10 nm to 1 µm.
and f) said coating comprising a member selected from the group consisting of gold, silica, silver, platinum, steel, cobalt, carbon, a polymer, and a combination thereof.
18. The composition of Claim 17, wherein:
a) said core particles have an average particle size of about 10 nm to 1 µm.
19. The composition of Claim 17, wherein:
a) said core particles have an average particle size of about 10 nm to 300 nm.
a) said core particles have an average particle size of about 10 nm to 300 nm.
20. The composition of Claim 17, wherein:
a) said core particles comprise a general shape selected from the group consisting of a sphere, a needle, a cube, an oval, irregular, a cylinder, a diamond, and a combination thereof.
a) said core particles comprise a general shape selected from the group consisting of a sphere, a needle, a cube, an oval, irregular, a cylinder, a diamond, and a combination thereof.
21. The composition of Claim 17, wherein:
a) said core particles comprise clusters.
a) said core particles comprise clusters.
22. The composition of Claim 17, wherein:
a) said core particles comprise the general shape of blood platelets.
a) said core particles comprise the general shape of blood platelets.
23. The composition of Claim 17, wherein:
a) said polymer is selected from the group consisting of polyethylene glycol, dextran, Tween, sorbitol, mannitol, and a combination thereof.
a) said polymer is selected from the group consisting of polyethylene glycol, dextran, Tween, sorbitol, mannitol, and a combination thereof.
24. The composition of Claim 17, wherein:
a) said coating has a thickness of about 5nm to 50nm.
a) said coating has a thickness of about 5nm to 50nm.
25. The composition of Claim 17, wherein:
a) said procoagulant molecules are selected from the group consisting of thrombin and Factor VII a.
a) said procoagulant molecules are selected from the group consisting of thrombin and Factor VII a.
26. The composition of Claim 17, further comprising:
a) a surfactant or dispersant.
a) a surfactant or dispersant.
27. The composition of Claim 17, wherein:
b) the concentration of said particulate material is about 0.1% to 70% (w/w) of the composition.
b) the concentration of said particulate material is about 0.1% to 70% (w/w) of the composition.
28. The composition of Claim 17, wherein:
a) said particulate material is non-toxic to bio-cells or biomolecules.
a) said particulate material is non-toxic to bio-cells or biomolecules.
29. The composition of Claim 17, wherein:
b) said carrier is selected from the group consisting of water, saline solution, sugar solution, Lactose Ringers, and blood plasma.
b) said carrier is selected from the group consisting of water, saline solution, sugar solution, Lactose Ringers, and blood plasma.
30. The composition of Claim 17, wherein:
a) said core particles have a narrow distribution of sizes.
a) said core particles have a narrow distribution of sizes.
31. The composition of Claim 17, wherein:
a) the magnetic particles comprise paramagnetic or superparamagnetic particles.
a) the magnetic particles comprise paramagnetic or superparamagnetic particles.
32. A method of controlling bleeding in a subject in need thereof, comprising the steps of:
a) administering to a subject having internal or external bleeding a predetermined amount of a hemostatic fluid;
b) the hemostatic fluid, comprising:
i) a carrier medium;
ii) a predetermined amount of a particulate material in the medium;
iii) the particulate material comprising core particles with a coating;
iv) the core particles having an average particle size of about 5 nm to 10 µm; and v) the coating comprising a member selected from the group consisting of gold, silica, silver, platinum, steel, cobalt, carbon,' a polymer, procoagulant molecules, and a combination thereof;
c) applying a magnetic field adjacent the site of a lesion causing the bleeding so as to form a cluster of the particulate material for thereby preventing the flow of blood through the lesion.
a) administering to a subject having internal or external bleeding a predetermined amount of a hemostatic fluid;
b) the hemostatic fluid, comprising:
i) a carrier medium;
ii) a predetermined amount of a particulate material in the medium;
iii) the particulate material comprising core particles with a coating;
iv) the core particles having an average particle size of about 5 nm to 10 µm; and v) the coating comprising a member selected from the group consisting of gold, silica, silver, platinum, steel, cobalt, carbon,' a polymer, procoagulant molecules, and a combination thereof;
c) applying a magnetic field adjacent the site of a lesion causing the bleeding so as to form a cluster of the particulate material for thereby preventing the flow of blood through the lesion.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/157,921 | 2002-05-31 | ||
| US10/157,921 US7670623B2 (en) | 2002-05-31 | 2002-05-31 | Hemostatic composition |
| PCT/US2003/014545 WO2003101429A1 (en) | 2002-05-31 | 2003-05-28 | A hemostatic composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2455510A1 true CA2455510A1 (en) | 2003-12-11 |
| CA2455510C CA2455510C (en) | 2010-04-06 |
Family
ID=29582568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2455510A Expired - Fee Related CA2455510C (en) | 2002-05-31 | 2003-05-28 | A hemostatic composition |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7670623B2 (en) |
| EP (1) | EP1509206B1 (en) |
| AT (1) | ATE429937T1 (en) |
| AU (1) | AU2003237809A1 (en) |
| CA (1) | CA2455510C (en) |
| DE (1) | DE60327431D1 (en) |
| WO (1) | WO2003101429A1 (en) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6860924B2 (en) * | 2002-06-07 | 2005-03-01 | Nanoscale Materials, Inc. | Air-stable metal oxide nanoparticles |
| US6817415B2 (en) * | 2002-11-05 | 2004-11-16 | Schlumberger Technology Corporation | Method of sealing an annulus surrounding a slotted liner |
| US8317002B2 (en) * | 2006-12-08 | 2012-11-27 | The Regents Of The University Of California | System of smart colloidal dampers with controllable damping curves using magnetic field and method of using the same |
| US8883194B2 (en) * | 2007-11-09 | 2014-11-11 | Honeywell International, Inc. | Adsorbent-containing hemostatic devices |
| US8795718B2 (en) * | 2008-05-22 | 2014-08-05 | Honeywell International, Inc. | Functional nano-layered hemostatic material/device |
| KR101967085B1 (en) | 2010-06-01 | 2019-04-08 | 백스터 인터내셔널 인코포레이티드 | Process for making dry and stable hemostatic compositions |
| BR112012030463B1 (en) | 2010-06-01 | 2021-08-24 | Baxter International Inc. | PROCESS TO MANUFACTURE A DRY AND STABLE HEMOSTATIC COMPOSITION, FINAL FINISHED CONTAINER, KIT TO MANAGE A HEMOSTATIC COMPOSITION, AND, THROMBINE COATED GRANULES |
| ES2682302T3 (en) | 2010-06-01 | 2018-09-19 | Baxter International Inc | Process for the production of dry and stable hemostatic compositions |
| RU2014125560A (en) * | 2011-11-25 | 2015-12-27 | Оцука Фармасьютикал Фэктори, Инк. | PHARMACEUTICAL COMPOSITION SUITABLE TO PREVENT ADHESION OR HEMOSTASIS |
| US20130197296A1 (en) * | 2012-01-13 | 2013-08-01 | Karl-Heinz Ott | Removing Cells from an Organism |
| WO2013131520A2 (en) | 2012-03-06 | 2013-09-12 | Ferrosan Medical Devices A/S | Pressurized container containing haemostatic paste |
| RU2636240C2 (en) | 2012-06-12 | 2017-11-21 | Ферросан Медикал Дивайсиз А/С | Dry haemostatic composition |
| US10034958B2 (en) | 2013-06-19 | 2018-07-31 | The Brigham And Women's Hospital, Inc. | Nanocomposite hydrogels |
| JP6390873B2 (en) | 2013-06-21 | 2018-09-19 | フェッローサン メディカル ディバイス エー／エス | Dry composition expanded under reduced pressure and syringe for holding the same |
| ES2941651T3 (en) * | 2013-12-10 | 2023-05-24 | Inst Nat Sante Rech Med | Procedures for adhering tissue surfaces and materials and biomedical uses thereof |
| RU2678592C1 (en) | 2013-12-11 | 2019-01-30 | Ферросан Медикал Дивайсиз А/С | Dry composition comprising extrusion enhancer |
| BR112017007466B1 (en) | 2014-10-13 | 2021-03-02 | Ferrosan Medical Devices A/S | method for preparing a dry composition, method for reconstituting the dry composition, paste, dry composition, container, homeostatic kit, and, using a dry composition |
| JP6747650B2 (en) | 2014-12-24 | 2020-08-26 | フェロサン メディカル デバイシーズ エイ／エス | Syringe for holding and mixing the first substance and the second substance |
| US10058490B2 (en) * | 2014-12-24 | 2018-08-28 | L'oreal | Acoustically-activated cosmetic hydrogels |
| US10918796B2 (en) | 2015-07-03 | 2021-02-16 | Ferrosan Medical Devices A/S | Syringe for mixing two components and for retaining a vacuum in a storage condition |
| EP4353311A2 (en) | 2015-07-20 | 2024-04-17 | The Brigham and Women's Hospital, Inc. | Shear-thinning compositions as an intravascular embolic agent |
| KR20210008479A (en) | 2018-05-09 | 2021-01-22 | 훼로산 메디칼 디바이스 에이/에스 | How to prepare a hemostatic composition |
Family Cites Families (153)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3047507A (en) * | 1960-04-04 | 1962-07-31 | Wefco Inc | Field responsive force transmitting compositions |
| US3127528A (en) * | 1960-10-03 | 1964-03-31 | United Aircraft Corp | Magnetohydrodynamic generator |
| US3287677A (en) | 1964-05-25 | 1966-11-22 | Westinghouse Electric Corp | High frequency transformer core comprised of magnetic fluid |
| US3488531A (en) * | 1965-09-15 | 1970-01-06 | Avco Corp | Means for and method of moving objects by ferrohydrodynamics |
| AU435693B2 (en) * | 1967-04-20 | 1973-05-14 | Ion-exchange adsorbents and process involving same | |
| US3767783A (en) | 1970-12-23 | 1973-10-23 | Us Interior | Self destructing pesticidal formulations and methods for their use |
| US3859789A (en) | 1972-01-31 | 1975-01-14 | Battelle Development Corp | Method and apparatus for converting one form of energy into another form of energy |
| US3937839A (en) * | 1974-02-28 | 1976-02-10 | American Home Products Corporation | Method for attenuating bleeding |
| US4106488A (en) * | 1974-08-20 | 1978-08-15 | Robert Thomas Gordon | Cancer treatment method |
| US4303636A (en) | 1974-08-20 | 1981-12-01 | Gordon Robert T | Cancer treatment |
| US4107288A (en) * | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
| US4064409A (en) | 1976-07-28 | 1977-12-20 | Redman Charles M | Ferrofluidic electrical generator |
| US4183156A (en) * | 1977-01-14 | 1980-01-15 | Robert C. Bogert | Insole construction for articles of footwear |
| DE2738253A1 (en) * | 1977-08-25 | 1979-03-01 | Dabisch Tipp Ex Tech | BODY WITH REVERSIBLE TEMPERATURE-DEPENDENT TRANSPARENCY |
| US4267234A (en) * | 1978-03-17 | 1981-05-12 | California Institute Of Technology | Polyglutaraldehyde synthesis and protein bonding substrates |
| US4340626A (en) * | 1978-05-05 | 1982-07-20 | Rudy Marion F | Diffusion pumping apparatus self-inflating device |
| US4219945B1 (en) * | 1978-06-26 | 1993-10-19 | Robert C. Bogert | Footwear |
| US4364377A (en) * | 1979-02-02 | 1982-12-21 | Walker Scientific, Inc. | Magnetic field hemostasis |
| US4321020A (en) * | 1979-12-17 | 1982-03-23 | Sperry Corporation | Fluid pump |
| US4323056A (en) * | 1980-05-19 | 1982-04-06 | Corning Glass Works | Radio frequency induced hyperthermia for tumor therapy |
| US4342157A (en) * | 1980-08-11 | 1982-08-03 | Sam Gilbert | Shock absorbing partially liquid-filled cushion for shoes |
| US4501726A (en) * | 1981-11-12 | 1985-02-26 | Schroeder Ulf | Intravascularly administrable, magnetically responsive nanosphere or nanoparticle, a process for the production thereof, and the use thereof |
| US4574782A (en) * | 1981-11-16 | 1986-03-11 | Corning Glass Works | Radio frequency-induced hyperthermia for tumor therapy |
| US4454234A (en) * | 1981-12-30 | 1984-06-12 | Czerlinski George H | Coated magnetizable microparticles, reversible suspensions thereof, and processes relating thereto |
| US4452773A (en) * | 1982-04-05 | 1984-06-05 | Canadian Patents And Development Limited | Magnetic iron-dextran microspheres |
| US4613304A (en) | 1982-10-21 | 1986-09-23 | Meyer Stanley A | Gas electrical hydrogen generator |
| US4443430A (en) * | 1982-11-16 | 1984-04-17 | Ethicon, Inc. | Synthetic absorbable hemostatic agent |
| US4472890A (en) | 1983-03-08 | 1984-09-25 | Fivel | Shoe incorporating shock absorbing partially liquid-filled cushions |
| US4545368A (en) | 1983-04-13 | 1985-10-08 | Rand Robert W | Induction heating method for use in causing necrosis of neoplasm |
| US4554088A (en) | 1983-05-12 | 1985-11-19 | Advanced Magnetics Inc. | Magnetic particles for use in separations |
| US4695393A (en) | 1983-05-12 | 1987-09-22 | Advanced Magnetics Inc. | Magnetic particles for use in separations |
| US4628037A (en) | 1983-05-12 | 1986-12-09 | Advanced Magnetics, Inc. | Binding assays employing magnetic particles |
| US4672040A (en) * | 1983-05-12 | 1987-06-09 | Advanced Magnetics, Inc. | Magnetic particles for use in separations |
| US4695392A (en) | 1983-05-12 | 1987-09-22 | Advanced Magnetics Inc. | Magnetic particles for use in separations |
| US4721618A (en) * | 1983-06-27 | 1988-01-26 | Queen's University At Kingston | Method for controlling bleeding |
| CA1225585A (en) * | 1983-06-30 | 1987-08-18 | Maria T. Litvinova | Composition for embolization of blood vessels |
| US4662359A (en) * | 1983-08-12 | 1987-05-05 | Robert T. Gordon | Use of magnetic susceptibility probes in the treatment of cancer |
| US4637394A (en) * | 1985-06-11 | 1987-01-20 | Racz Gabor B | Constant pressure tourniquet |
| US5597531A (en) * | 1985-10-04 | 1997-01-28 | Immunivest Corporation | Resuspendable coated magnetic particles and stable magnetic particle suspensions |
| US5180583A (en) * | 1985-11-26 | 1993-01-19 | Hedner Ulla K E | Method for the treatment of bleeding disorders |
| US5069216A (en) | 1986-07-03 | 1991-12-03 | Advanced Magnetics Inc. | Silanized biodegradable super paramagnetic metal oxides as contrast agents for imaging the gastrointestinal tract |
| US4951675A (en) * | 1986-07-03 | 1990-08-28 | Advanced Magnetics, Incorporated | Biodegradable superparamagnetic metal oxides as contrast agents for MR imaging |
| US4770183A (en) * | 1986-07-03 | 1988-09-13 | Advanced Magnetics Incorporated | Biologically degradable superparamagnetic particles for use as nuclear magnetic resonance imaging agents |
| US6013531A (en) * | 1987-10-26 | 2000-01-11 | Dade International Inc. | Method to use fluorescent magnetic polymer particles as markers in an immunoassay |
| DE3738989A1 (en) | 1987-11-17 | 1989-05-24 | Hans Werding | Electrical generator |
| US4834898A (en) * | 1988-03-14 | 1989-05-30 | Board Of Control Of Michigan Technological University | Reagents for magnetizing nonmagnetic materials |
| US4992190A (en) * | 1989-09-22 | 1991-02-12 | Trw Inc. | Fluid responsive to a magnetic field |
| US5374246A (en) | 1989-11-07 | 1994-12-20 | Ray; Joel W. | Method and device for delivering a hemostatic agent to an operating status |
| FR2656319B1 (en) * | 1989-12-27 | 1992-03-20 | Rhone Poulenc Chimie | MAGNETISABLE COMPOSITE MICROSPHERES BASED ON A CROSSLINKED ORGANOSILICY POLYMER, THEIR PREPARATION PROCESS AND THEIR APPLICATION IN BIOLOGY. |
| US5067952A (en) | 1990-04-02 | 1991-11-26 | Gudov Vasily F | Method and apparatus for treating malignant tumors by local hyperpyrexia |
| US5595735A (en) * | 1990-05-23 | 1997-01-21 | Johnson & Johnson Medical, Inc. | Hemostatic thrombin paste composition |
| US5236410A (en) * | 1990-08-02 | 1993-08-17 | Ferrotherm International, Inc. | Tumor treatment method |
| EP0470569B1 (en) * | 1990-08-08 | 1995-11-22 | Takeda Chemical Industries, Ltd. | Intravascular embolizing agent containing angiogenesis inhibiting substance |
| US5466609A (en) | 1990-10-31 | 1995-11-14 | Coulter Corporation | Biodegradable gelatin-aminodextran particle coatings of and processes for making same |
| US5108359A (en) * | 1990-12-17 | 1992-04-28 | Ferrotherm International, Inc. | Hemangioma treatment method |
| US6391343B1 (en) * | 1991-01-15 | 2002-05-21 | Hemosphere, Inc. | Fibrinogen-coated particles for therapeutic use |
| US5161776A (en) | 1991-02-11 | 1992-11-10 | Nicholson Robert D | High speed electric valve |
| US5155927A (en) * | 1991-02-20 | 1992-10-20 | Asics Corporation | Shoe comprising liquid cushioning element |
| DE4117782C2 (en) * | 1991-05-28 | 1997-07-17 | Diagnostikforschung Inst | Nanocrystalline magnetic iron oxide particles, processes for their production and diagnostic and / or therapeutic agents |
| FR2676927B1 (en) * | 1991-05-29 | 1995-06-23 | Ibf | MICROSPHERES FOR USE IN THERAPEUTIC VASCULAR OCCLUSIONS AND INJECTABLE SOLUTIONS CONTAINING THEM. |
| US5079786A (en) * | 1991-07-12 | 1992-01-14 | Rojas Adrian Q | Cushion with magnetic spheres in a viscous fluid |
| US5207675A (en) * | 1991-07-15 | 1993-05-04 | Jerome Canady | Surgical coagulation device |
| JP3356447B2 (en) * | 1991-10-16 | 2002-12-16 | テルモ株式会社 | Vascular lesion embolic material composed of dried polymer gel |
| US5965194A (en) | 1992-01-10 | 1999-10-12 | Imation Corp. | Magnetic recording media prepared from magnetic particles having an extremely thin, continuous, amorphous, aluminum hydrous oxide coating |
| US6036955A (en) * | 1992-03-05 | 2000-03-14 | The Scripps Research Institute | Kits and methods for the specific coagulation of vasculature |
| JP3241726B2 (en) * | 1992-04-14 | 2001-12-25 | バイロコープ サイエンティフィク，インコーポレイティド | Magnetorheological fluid and method for producing the same |
| WO1993021844A1 (en) * | 1992-04-23 | 1993-11-11 | Scimed Life Systems, Inc. | Apparatus and method for sealing vascular punctures |
| US6235313B1 (en) * | 1992-04-24 | 2001-05-22 | Brown University Research Foundation | Bioadhesive microspheres and their use as drug delivery and imaging systems |
| US5567564A (en) | 1992-07-09 | 1996-10-22 | Xerox Corporation | Liquid development composition having a colorant comprising a stable dispersion of magnetic particles in an aqueous medium |
| US5358659A (en) | 1992-07-09 | 1994-10-25 | Xerox Corporation | Magnetic materials with single-domain and multidomain crystallites and a method of preparation |
| US6319599B1 (en) | 1992-07-14 | 2001-11-20 | Theresa M. Buckley | Phase change thermal control materials, method and apparatus |
| US5702630A (en) | 1992-07-16 | 1997-12-30 | Nippon Oil Company, Ltd. | Fluid having both magnetic and electrorheological characteristics |
| US5354488A (en) | 1992-10-07 | 1994-10-11 | Trw Inc. | Fluid responsive to a magnetic field |
| CA2147990C (en) * | 1992-10-30 | 2001-02-20 | Keith D. Weiss | Low viscosity magnetorheological materials |
| US5582425A (en) | 1993-02-08 | 1996-12-10 | Autoliv Development Ab | Gas supply device for an air-bag |
| US5885486A (en) * | 1993-03-05 | 1999-03-23 | Pharmaciaand Upjohn Ab | Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof |
| US5348050A (en) | 1993-07-19 | 1994-09-20 | Ashton Thomas E | Magnetic fluid treatment device |
| DE4325071C2 (en) | 1993-07-19 | 1995-08-10 | Lancaster Group Ag | Preparation for circulation promotion |
| US5565215A (en) | 1993-07-23 | 1996-10-15 | Massachusettes Institute Of Technology | Biodegradable injectable particles for imaging |
| US5673721A (en) | 1993-10-12 | 1997-10-07 | Alcocer; Charles F. | Electromagnetic fluid conditioning apparatus and method |
| US5646185A (en) * | 1993-10-14 | 1997-07-08 | The Board Of Trustees Of The Leland Stanford Junior University | Tumor treatment method |
| CA2175203A1 (en) * | 1993-11-03 | 1995-05-11 | Thaddeus P. Pruss | Hemostatic patch |
| JP3436760B2 (en) * | 1994-07-27 | 2003-08-18 | ハーバート ピルグリム | Superparamagnetic particles |
| US5549837A (en) * | 1994-08-31 | 1996-08-27 | Ford Motor Company | Magnetic fluid-based magnetorheological fluids |
| US6266897B1 (en) * | 1994-10-21 | 2001-07-31 | Adidas International B.V. | Ground-contacting systems having 3D deformation elements for use in footwear |
| US5714829A (en) * | 1995-01-10 | 1998-02-03 | Guruprasad; Venkata | Electromagnetic heat engines and method for cooling a system having predictable bursts of heat dissipation |
| US5635162A (en) * | 1995-02-23 | 1997-06-03 | Ultradent Products, Inc. | Hemostatic composition for treating gingival area |
| US5650681A (en) * | 1995-03-20 | 1997-07-22 | Delerno; Charles Chaille | Electric current generation apparatus |
| US5782954A (en) * | 1995-06-07 | 1998-07-21 | Hoeganaes Corporation | Iron-based metallurgical compositions containing flow agents and methods for using same |
| US5958794A (en) | 1995-09-22 | 1999-09-28 | Minnesota Mining And Manufacturing Company | Method of modifying an exposed surface of a semiconductor wafer |
| US5900184A (en) * | 1995-10-18 | 1999-05-04 | Lord Corporation | Method and magnetorheological fluid formulations for increasing the output of a magnetorheological fluid device |
| US6189538B1 (en) * | 1995-11-20 | 2001-02-20 | Patricia E. Thorpe | Tourniquet and method of using |
| US5800372A (en) | 1996-01-09 | 1998-09-01 | Aerojet-General Corporation | Field dressing for control of exsanguination |
| US5702361A (en) * | 1996-01-31 | 1997-12-30 | Micro Therapeutics, Inc. | Method for embolizing blood vessels |
| US5813142A (en) | 1996-02-09 | 1998-09-29 | Demon; Ronald S. | Shoe sole with an adjustable support pattern |
| US5667715A (en) | 1996-04-08 | 1997-09-16 | General Motors Corporation | Magnetorheological fluids |
| DE29607363U1 (en) * | 1996-04-23 | 1996-08-22 | Buerkert Werke Gmbh & Co | Valve through which gas flows |
| AUPN978296A0 (en) | 1996-05-10 | 1996-05-30 | Gray, Bruce N | Targeted hysteresis hyperthermia as a method for treating cancer |
| US5695480A (en) | 1996-07-29 | 1997-12-09 | Micro Therapeutics, Inc. | Embolizing compositions |
| WO1998019965A1 (en) * | 1996-11-04 | 1998-05-14 | Materials Modification, Inc. | Microwave plasma chemical synthesis of ultrafine powders |
| US6815063B1 (en) | 1996-11-16 | 2004-11-09 | Nanomagnetics, Ltd. | Magnetic fluid |
| US5707078A (en) * | 1996-11-26 | 1998-01-13 | Takata, Inc. | Air bag module with adjustable cushion inflation |
| US6036226A (en) * | 1997-02-03 | 2000-03-14 | General Dynamics Armament Systems, Inc. | Inflator capable of modulation air bag inflation rate in a vehicle occupant restraint apparatus |
| US6039347A (en) * | 1997-02-03 | 2000-03-21 | General Dynamics Armament Systems, Inc. | Liquid propellant airbag inflator with dual telescoping pistons |
| US5993358A (en) | 1997-03-05 | 1999-11-30 | Lord Corporation | Controllable platform suspension system for treadmill decks and the like and devices therefor |
| US6076852A (en) * | 1997-08-05 | 2000-06-20 | Trw Vehicle Safety Systems Inc. | Inflatable restraint inflator with flow control valve |
| US6083680A (en) * | 1997-08-14 | 2000-07-04 | Fuji Photo Film Co., Ltd. | Photothermographic material |
| JPH11107907A (en) * | 1997-10-04 | 1999-04-20 | Yoshiro Nakamatsu | Convection energy apparatus |
| AUPP008197A0 (en) | 1997-10-29 | 1997-11-20 | Paragon Medical Limited | Improved targeted hysteresis hyperthermia as a method for treating diseased tissue |
| US5927753A (en) * | 1997-12-15 | 1999-07-27 | Trw Vehicle Safety Systems Inc. | Vehicle occupant protection apparatus |
| US5947514A (en) | 1998-02-20 | 1999-09-07 | Breed Automotive Technology, Inc. | Valve controlled automotive pyrotechnic systems |
| WO1999049930A1 (en) * | 1998-03-30 | 1999-10-07 | University Of Virginia Patent Foundation | Flow arrest, double balloon technique for occluding aneurysms or blood vessels |
| DE19816208B4 (en) * | 1998-04-09 | 2009-04-23 | Knorr-Bremse Systeme für Schienenfahrzeuge GmbH | control valve |
| US6399317B1 (en) * | 1998-04-15 | 2002-06-04 | Utah State University | Real time detection of antigens |
| JP3907837B2 (en) | 1998-06-12 | 2007-04-18 | 富士フイルム株式会社 | Image recording material |
| US6051607A (en) * | 1998-07-02 | 2000-04-18 | Micro Therapeutics, Inc. | Vascular embolizing compositions comprising ethyl lactate and methods for their use |
| US6315709B1 (en) | 1998-08-07 | 2001-11-13 | Stereotaxis, Inc. | Magnetic vascular defect treatment system |
| US6149832A (en) | 1998-10-26 | 2000-11-21 | General Motors Corporation | Stabilized magnetorheological fluid compositions |
| DE29821232U1 (en) | 1998-11-26 | 1999-04-01 | Trw Airbag Sys Gmbh & Co Kg | Gas generator for a security system |
| EP1138743A4 (en) | 1998-11-27 | 2005-01-19 | Nittetsu Mining Co Ltd | Fluorescent or phosphorescent composition |
| US6312484B1 (en) | 1998-12-22 | 2001-11-06 | 3M Innovative Properties Company | Nonwoven abrasive articles and method of preparing same |
| US6296604B1 (en) * | 1999-03-17 | 2001-10-02 | Stereotaxis, Inc. | Methods of and compositions for treating vascular defects |
| US6238403B1 (en) | 1999-10-04 | 2001-05-29 | Microvention, Inc. | Filamentous embolic device with expansible elements |
| US6266146B1 (en) | 1999-12-03 | 2001-07-24 | University Of Central Florida | Ferrofluid 3-D gyroscope and light modulator |
| JP2001247010A (en) * | 1999-12-28 | 2001-09-11 | Takata Corp | Occupant protective device |
| US6358196B1 (en) * | 1999-12-29 | 2002-03-19 | Reiza Rayman | Magnetic retraction system for laparoscopic surgery and method of use thereof |
| ATE235960T1 (en) | 2000-01-13 | 2003-04-15 | Kureha Chemical Ind Co Ltd | MICRO CAPSULE AND ITS PRODUCTION PROCESS |
| US6475710B2 (en) | 2000-01-20 | 2002-11-05 | Konica Corporation | Photothermographic material |
| US6530944B2 (en) * | 2000-02-08 | 2003-03-11 | Rice University | Optically-active nanoparticles for use in therapeutic and diagnostic methods |
| AU2001241642A1 (en) | 2000-02-18 | 2001-08-27 | The Board Of Regents Of The University And Community College System Of Nevada | Magnetorheological polymer gels |
| US6548264B1 (en) * | 2000-05-17 | 2003-04-15 | University Of Florida | Coated nanoparticles |
| US6355275B1 (en) * | 2000-06-23 | 2002-03-12 | Carbon Medical Technologies, Inc. | Embolization using carbon coated microparticles |
| WO2002002034A1 (en) | 2000-06-30 | 2002-01-10 | Roland J. Christensen, As Operating Manager Of Rjc Development, Lc, General Partner Of The Roland J. Christensen Family Limited Partnership | Prosthetic foot |
| FR2811571B1 (en) * | 2000-07-11 | 2002-10-11 | Flamel Tech Sa | ORAL PHARMACEUTICAL COMPOSITION FOR CONTROLLED RELEASE AND SUSTAINED ABSORPTION OF AN ACTIVE INGREDIENT |
| US6683333B2 (en) * | 2000-07-14 | 2004-01-27 | E Ink Corporation | Fabrication of electronic circuit elements using unpatterned semiconductor layers |
| US6649138B2 (en) * | 2000-10-13 | 2003-11-18 | Quantum Dot Corporation | Surface-modified semiconductive and metallic nanoparticles having enhanced dispersibility in aqueous media |
| US6443993B1 (en) | 2001-03-23 | 2002-09-03 | Wayne Koniuk | Self-adjusting prosthetic ankle apparatus |
| US6582429B2 (en) * | 2001-07-10 | 2003-06-24 | Cardiac Pacemakers, Inc. | Ablation catheter with covered electrodes allowing electrical conduction therethrough |
| US6557272B2 (en) * | 2001-07-13 | 2003-05-06 | Luigi Alessio Pavone | Helium movement magnetic mechanism adjustable socket sole |
| US7101862B2 (en) | 2001-12-31 | 2006-09-05 | Area Laboratories, Llc | Hemostatic compositions and methods for controlling bleeding |
| US6489694B1 (en) | 2002-01-22 | 2002-12-03 | Jacob Chass | Ferrofluidic, electrical power generator |
| US6734574B2 (en) * | 2002-02-13 | 2004-05-11 | Ernest Eun Ho Shin | Buoyancy-driven electric power generator |
| US6768230B2 (en) * | 2002-02-19 | 2004-07-27 | Rockwell Scientific Licensing, Llc | Multiple magnet transducer |
| US6702858B2 (en) | 2002-05-15 | 2004-03-09 | Roland J. Christensen | Liner for prosthetic socket with variable viscosity fluid |
| US7249604B1 (en) * | 2002-05-10 | 2007-07-31 | Vasmo, Inc. | Medical devices for occlusion of blood flow |
| US6789820B2 (en) | 2002-06-26 | 2004-09-14 | Trw Vehicle Safety Systems Inc. | Variable output inflator |
| US7288075B2 (en) * | 2002-06-27 | 2007-10-30 | Ethicon, Inc. | Methods and devices utilizing rheological materials |
| DE10333703B4 (en) * | 2002-07-24 | 2007-04-26 | Völkl Tennis GmbH | Ball game racket |
| DE10240530A1 (en) * | 2002-09-03 | 2004-03-11 | Völkl Tennis GmbH | Shoe, in particular, a sports shoe comprises a sole with additional middle and top zones accommodating respectively force sensors and active damping devices |
| US6871871B2 (en) * | 2002-09-13 | 2005-03-29 | Island Pyrochemical Industries Corp. | Air bag inflator |
| US7007972B1 (en) * | 2003-03-10 | 2006-03-07 | Materials Modification, Inc. | Method and airbag inflation apparatus employing magnetic fluid |
| US6982501B1 (en) * | 2003-05-19 | 2006-01-03 | Materials Modification, Inc. | Magnetic fluid power generator device and method for generating power |
| US7200956B1 (en) * | 2003-07-23 | 2007-04-10 | Materials Modification, Inc. | Magnetic fluid cushioning device for a footwear or shoe |
-
2002
- 2002-05-31 US US10/157,921 patent/US7670623B2/en not_active Expired - Lifetime
-
2003
- 2003-05-28 EP EP03736570A patent/EP1509206B1/en not_active Expired - Lifetime
- 2003-05-28 DE DE60327431T patent/DE60327431D1/en not_active Expired - Fee Related
- 2003-05-28 CA CA2455510A patent/CA2455510C/en not_active Expired - Fee Related
- 2003-05-28 WO PCT/US2003/014545 patent/WO2003101429A1/en not_active Application Discontinuation
- 2003-05-28 AT AT03736570T patent/ATE429937T1/en not_active IP Right Cessation
- 2003-05-28 AU AU2003237809A patent/AU2003237809A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2455510C (en) | 2010-04-06 |
| DE60327431D1 (en) | 2009-06-10 |
| EP1509206A1 (en) | 2005-03-02 |
| US7670623B2 (en) | 2010-03-02 |
| US20030224056A1 (en) | 2003-12-04 |
| WO2003101429A1 (en) | 2003-12-11 |
| AU2003237809A1 (en) | 2003-12-19 |
| EP1509206B1 (en) | 2009-04-29 |
| ATE429937T1 (en) | 2009-05-15 |
| EP1509206A4 (en) | 2006-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2455510A1 (en) | A hemostatic composition | |
| Gao et al. | Shape-controlled synthesis and magnetic properties of monodisperse Fe3O4 nanocubes | |
| Behrens et al. | Magnetic nanocomposites | |
| CA2560892C (en) | Magnetic nanoparticles of noble metals | |
| Frey et al. | Magnetic nanoparticles: synthesis, functionalization, and applications in bioimaging and magnetic energy storage | |
| Teng et al. | Synthesis of face-centered tetragonal FePt nanoparticles and granular films from Pt@ Fe2O3 Core− Shell nanoparticles | |
| Kim et al. | From core/shell structured FePt/Fe3O4/MgO to ferromagnetic FePt nanoparticles | |
| US20150068219A1 (en) | High Porosity Particulate Beds Structurally Stabilized by Epoxy | |
| Egizbek et al. | Stability and cytotoxicity study of NiFe2O4 nanocomposites synthesized by co-precipitation and subsequent thermal annealing | |
| ZA200304130B (en) | Bone cement mixture and X-ray contrast medium as well as method for their preparation. | |
| Alpers et al. | Congenital (infantile) hemangiopericytoma of the tongue and sublingual region | |
| Schwartz et al. | Giant basal cell carcinoma with metastases and myelophthisic anemia | |
| Mohamed | Ultrastructure of glycogen‐rich clear cell carcinoma of the palate | |
| Abedini-Nassab et al. | Recent patents and advances on applications of magnetic nanoparticles and thin films in cell manipulation | |
| CN1725302B (en) | Recording medium substrate and recording medium having an electroless plating film with a good film quality | |
| AU2006203585B2 (en) | A hemostatic composition | |
| JPS5846607A (en) | Manufacture of magnetic metal powder | |
| JPS62139122A (en) | Fine plate ba ferrite corpuscle powder for magnetic recording and its production | |
| Sinha et al. | Magnetic field–induced biomimetic synthesis of superparamagnetic poly (vinyl alcohol)–maghemite composite | |
| JPS63287099A (en) | Magnetic powder for magnetic shield | |
| Leder | Subtle clues to diagnosis by histochemistry: Mast cell disease | |
| Qin et al. | Soft magnetic nanomaterials towards nanomedicine: magnetism principles, preparation, characterization and potential applications | |
| JPS62139124A (en) | Fine plate ba ferrite corpuscle powder for magnetic recording and its production | |
| McNamara et al. | Nanoalloys: 10. Biomedical applications of nanoalloys | |
| JPS60160028A (en) | Vertically magnetized recording body |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20210528 |